[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353878-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353878-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-hkdc1-ass1-acsbg2-axis-reprograms-lipid-metabolism-to-drive-therapeutic-resistance-in-hepatocellular-carcinoma","The HKDC1-ASS1-ACSBG2 axis reprograms lipid metabolism to drive therapeutic resistance in hepatocellular carcinoma","","Hepatocellular carcinoma (HCC) shows profound metabolic reprogramming, especially abnormal lipid metabolism, yet existing therapies provide limited benefit. This study investigates how the HKDC1-ASS1-ACSBG2 axis reshapes lipid metabolism and contributes to therapeutic resistance in HCC. Clinical specimens and multiple cell and in vivo models evaluate gene function and mechanisms linking HKDC1 stabilization of ASS1, acetyl-CoA accumulation, ACSBG2 activation, lipogenesis, tumor growth, and lenvatinib resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-hkdc1-ass1-acsbg2-axis-reprograms-lipid-metabolism-to-drive-therapeutic-resistance-in-hepatocellular-carcinoma/353878/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-hkdc1-ass1-acsbg2-axis-reprograms-lipid-metabolism-to-drive-therapeutic-resistance-in-hepatocellular-carcinoma/353878.png","ImageObject",300,407,{"name":42,"@type":43},"Mia  ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of the study?","Question",{"text":63,"@type":64},"The study examines how the HKDC1-ASS1-ACSBG2 axis reprograms lipid metabolism to drive therapeutic resistance in hepatocellular carcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does HKDC1 influence ASS1 and lipid metabolism?",{"text":68,"@type":64},"HKDC1 interacts with ASS1 and inhibits ubiquitin-mediated degradation, stabilizing ASS1 and increasing glutamine-derived acetyl-CoA production.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does ACSBG2 play in tumor growth and treatment resistance?",{"text":72,"@type":64},"Accumulated acetyl-CoA activates ACSBG2 through histone H3 acetylation, promoting lipogenesis and HCC proliferation, and contributing to lenvatinib resistance in vitro and in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353878,1790196482,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Ling et al. Journal of Translational Medicine (2026) 24:373  \n[https://doi.org/10.1186/s12967-026-07779-x](https://doi.org/10.1186/s12967-026-07779-x)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nThe HKDC1-ASS1-ACSBG2 axis reprograms lipid metabolism to drive therapeutic resistance in hepatocellular carcinoma  \nXiangyu Ling1,2†, Wenhu Zhao1,2†, Kuan Li3†, Litao Liang1,2, Wenbo Jia1,2, Jinyi Wang1,2, Yanzhi Feng1,2, Chao Xu1,2, Qingpeng Lv1,2, Zhiwen Feng1,2, Deming Zhu1,2*, Lianbao Kong1,2* and Wenzhou Ding1,2*  \nAbstract  \nBackground Hepatocellular carcinoma (HCC) is a lethal malignancy characterized by profound metabolic reprogramming, notably aberrant lipid metabolism. Current therapeutic strategies offer limited efficacy, highlighting the critical need to identify its metabolic vulnerabilities. This study aims to investigate the role of the HKDC1-ASS1-ACSBG2 axis in lipid metabolic reprogramming and therapeutic resistance in HCC.  \nMethods Using clinical HCC specimens and cell lines, we systematically evaluated the functions and mechanisms of HKDC1, ASS1, and ACSBG2 in lipogenesis, cell proliferation, and drug response via RNA sequencing,  \nco-immunoprecipitation, immunofluorescence, ubiquitination assays, dual-luciferase reporter assays, cellular functional experiments, and nude mouse xenograft models.  \nResults HKDC1 was highly expressed in HCC and correlated with poor patient prognosis. Mechanistically, HKDC1 interacts with ASS1 (310–412 aa) via its HKLS1 domain, inhibiting ubiquitin-mediated degradation and stabilizing ASS1. This enhances the production of glutamine-derived acetyl-CoA. The accumulated acetyl-CoA transcriptionally activates ACSBG2 by inducing histone H3 acetylation, thereby driving lipid biosynthesis and HCC cell proliferation. This axis operates distinctly from the FASN-dependent pathway and promotes lenvatinib resistance both in vitro and in vivo.  \nConclusion Our study unveils a novel metabolic regulatory axis, HKDC1-ASS1-ACSBG2, that promotes lipogenesis and tumor progression in HCC by integrating multiple metabolic pathways, and confers lenvatinib resistance. Targeting this axis may present a novel therapeutic strategy to overcome treatment resistance in this recalcitrant malignancy.  \n†Xiangyu Ling, Wenhu Zhao and Kuan Li contributed equally to this work.  \n*Correspondence:  \nDeming Zhu [chinazdm@yeah.net](chinazdm@yeah.net)[ ](chinazdm@yeah.net)Lianbao Kong [lbkong@njmu.edu.cn](lbkong@njmu.edu.cn)[ ](lbkong@njmu.edu.cn)Wenzhou Ding [dingwenzhou@njmu.edu.cn](dingwenzhou@njmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nLing et al. Journal of Translational Medicine (2026) 24:373 Page 2 of 20  \nKeywords Hepatocellular carcinoma, Lipid metabolism, Therapeutic resistance, HKDC1-ASS1-ACSBG2 axis, De novo lipogenesis  \nGraphical Abstract  \nIntroduction  \nHepatocellular carcinoma (HCC), the predominant form of primary liver malignancy, continues to pose significant clinical challenges with persisten","cbCaimLpmHrRnW5H","https://ap.wps.com/l/cbCaimLpmHrRnW5H","pdf",10694053,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Graphical Abstract\n# Introduction","[{\"question\":\"What is the main focus of the study?\",\"answer\":\"The study examines how the HKDC1-ASS1-ACSBG2 axis reprograms lipid metabolism to drive therapeutic resistance in hepatocellular carcinoma.\"},{\"question\":\"How does HKDC1 influence ASS1 and lipid metabolism?\",\"answer\":\"HKDC1 interacts with ASS1 and inhibits ubiquitin-mediated degradation, stabilizing ASS1 and increasing glutamine-derived acetyl-CoA production.\"},{\"question\":\"What role does ACSBG2 play in tumor growth and treatment resistance?\",\"answer\":\"Accumulated acetyl-CoA activates ACSBG2 through histone H3 acetylation, promoting lipogenesis and HCC proliferation, and contributing to lenvatinib resistance in vitro and in vivo.\"}]","The HKDC1-ASS1-ACSBG2 axis reprograms lipid metabolism to drive therapeutic resistance in hepatocellular carcinoma | PDF",1790107699,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76ddd41d5e25f9716c4231286881c771.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd1236d4fcbb20c040372e0f2a21a21f.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c48c3c6aadd2f8b976dfc3add233d7a.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78ed01bf5a4cda4e395d10e26444ef71.webp",980,1306]